Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Aktis Oncology, Inc. (Nasdaq: AKTS), a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. While specific SEC filings are not listed in the provided information, a Nasdaq-listed issuer such as Aktis Oncology would typically use SEC reports to describe its business, pipeline, risks, and capital structure in more detail.
Annual and quarterly reports, such as Forms 10-K and 10-Q when available, generally provide narrative and financial disclosure about companies like Aktis Oncology. For a clinical-stage radiopharmaceutical company, these documents often include descriptions of its miniprotein radioconjugate platform, targeted tumor types, clinical development plans, and factors that could affect its research and development activities.
Registration statements, such as the Form S-1 that Aktis Oncology reports was declared effective in connection with its initial public offering, offer additional background on the company’s history, founding, and the structure of its capital raising transactions. Aktis Oncology has stated that its common stock began trading on the Nasdaq Global Select Market under the ticker AKTS following the effectiveness of its Form S-1.
On this filings page, Stock Titan’s tools can be used to review such documents when they are available from the SEC’s EDGAR system. AI-powered summaries are designed to highlight key sections of lengthy filings, such as business descriptions, risk factors related to clinical development and radiopharmaceutical safety, and disclosures about collaborations like the company’s strategic relationship with Eli Lilly and Company.
Users interested in AKTS can use this page to monitor new filings as they appear, compare successive disclosures, and better understand how Aktis Oncology presents its radiopharmaceutical platform, pipeline candidates, and single operating segment focused on research and development in official regulatory documents.
Aktis Oncology large shareholders affiliated with MPM BioVentures 2018 reported major equity changes tied to the company’s initial public offering. On January 12, 2026, entities in the group converted Series Seed, Series A and Series B Redeemable Convertible Preferred Stock into common shares at a 3.8044-for-1 ratio, resulting in 1,314,262, 5,914,197 and 1,577,119 shares of common stock from each series, respectively. The group also reported purchasing an additional 1,112,777 common shares at $18 per share. Following these transactions, the reporting entities indirectly held a total of 10,260,064 Aktis Oncology common shares spread across several investment funds. The reporting persons state that they disclaim beneficial ownership except to the extent of their pecuniary interest.
Aktis Oncology insider funds reported major share conversions and a purchase tied to its initial public offering. On January 12, 2026, investment entities linked to MPM converted 5,000,000 Series Seed, 22,500,000 Series A and 6,000,000 Series B Redeemable Convertible Preferred Stock into common shares at a 3.8044‑for‑1 rate, issuing 1,314,262, 5,914,197 and 1,577,119 common shares, respectively.
These common shares are held across multiple MPM vehicles, including MPM Asset Management LLC, several MPM BioVentures funds, MPM Oncology funds and Oncology Impact Private Investment Fund 2, L.P. The MPM‑affiliated funds also purchased 1,112,777 shares of Aktis Oncology common stock at $18 per share, bringing their indirectly held common stock to 10,260,064 shares. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Aktis Oncology, Inc. received a large shareholder disclosure showing that Vida Ventures funds and related entities, together with director Helen Kim, beneficially own about 10.9% of the company’s common stock, based on 53,296,950 shares outstanding. Vida Ventures II, LLC holds 5,671,825 shares (10.6% of the class) and Vida Ventures II-A, LLC holds 157,387 shares (0.3%), all managed by VV Manager II, LLC.
The filing explains that these positions were built through multiple preferred stock investments in 2021–2024 that converted to common stock at the IPO, plus purchases in the offering at $18.00 per share. Helen Kim is a board member and holds 2,103 shares subject to stock options exercisable within 60 days, in addition to the Vida-related holdings. Vida II, Vida II-A and Ms. Kim have entered into 180-day lock-up agreements and hold registration and other rights under an investors’ rights agreement, while stating they may adjust their stake over time for general investment purposes.
Aktis Oncology, Inc. director-affiliated investment funds advised by EcoR1 Capital, LLC reported a series of equity transactions in connection with the company’s initial public offering. On January 12, 2026, shares of Series A and Series B Redeemable Convertible Preferred Stock held by EcoR1-advised funds converted into Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately before the IPO closing for no additional consideration.
The filing also shows the EcoR1-advised funds purchased 2,077,779 and 144,443 shares of Common Stock at $18 per share. Each share of Class A Common Stock is convertible into one share of Common Stock at the holder’s election for no additional consideration, subject to a 4.99% beneficial ownership limitation. The securities are held by EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P., and EcoR1 Venture Opportunity Fund, L.P.; EcoR1 and Oleg Nodelman may be deemed to indirectly beneficially own them but disclaim beneficial ownership beyond their pecuniary interests.
Vida Ventures II, LLC and Vida Ventures II-A, LLC, both 10% owners of Aktis Oncology, Inc., reported multiple transactions dated 01/12/2026. Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Common Stock on a 3.8044-for-1 basis immediately before the closing of Aktis Oncology’s initial public offering, with no additional consideration paid.
Following these conversions and open-market purchases, Vida Ventures II, LLC indirectly held 5,671,825 shares of Common Stock after acquiring 4,859,370 shares through conversion and buying 812,455 shares at $18 per share. Vida Ventures II-A, LLC indirectly held 157,387 shares of Common Stock after receiving 134,842 shares through conversion and purchasing 22,545 shares at $18 per share.
Aktis Oncology, Inc. director and 10% owner Kim Helen Susan reported indirect ownership changes tied to the company’s initial public offering. Investment entities Vida Ventures II, LLC and Vida Ventures II-A, LLC converted their Series A and Series B Redeemable Convertible Preferred Stock into Common Stock on a 3.8044-for-1 basis immediately before the IPO closing, with no additional cash paid. Following these conversions and additional purchases at $18 per share on the same date, Vida Ventures II, LLC held 5,671,825 shares of Common Stock and Vida Ventures II-A, LLC held 157,387 shares, over which various Vida Ventures entities and committee members, including the reporting person, may be deemed to share voting and investment power, subject to pecuniary-interest disclaimers.
Aktis Oncology, Inc. director Segal Lloyd Mitchell reported an automatic conversion of preferred stock into common shares tied to the company’s initial public offering. On 01/12/2026, Arvala, Inc., an entity for which Mitchell is president and sole stockholder, converted 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock into the issuer’s common stock on a 3.8044-for-1 basis without any cash payment. This conversion resulted in 19,631 shares of common stock, all held indirectly through Arvala, Inc., and reflects the automatic conversion that occurred immediately before the closing of the IPO.
Aktis Oncology, Inc. adopted an amended and restated certificate of incorporation and bylaws in connection with the completion of its initial public offering on January 12, 2026. The new charter authorizes 480,000,000 shares of common stock, 10,000,000 shares of Class A common stock, and 10,000,000 shares of undesignated preferred stock that the board may issue in one or more series. It also eliminates prior preferred stock series, requires at least a two-thirds stockholder vote to remove a director for cause, creates a classified board with directors serving staggered three-year terms, and removes stockholder action by written consent.
The amended and restated bylaws, effective immediately prior to the IPO, establish detailed procedures for stockholder proposals and director nominations, revise indemnification provisions for directors and officers, and align the bylaws with the new charter terms.
Aktis Oncology, Inc. Chief Financial Officer Kyle D. Kuvalanka filed an initial Form 3 reporting his beneficial ownership of stock options in the company. He directly holds a stock option to buy 370,423 shares of common stock at an exercise price of $11.46 per share, exercisable until 12/11/2035, and another option to buy 131,426 shares at $18 per share, exercisable until 01/07/2036.
For the first option grant, 25% of the shares will vest on November 3, 2026, with the remainder vesting in equal monthly installments over the following three years, subject to his continued service. For the second grant, 25% of the shares will vest on January 8, 2027, with the balance vesting monthly thereafter on the same continued-service condition. The filing does not show any stock sales or purchases, only these option holdings.
Aktis Oncology director and 10% owner Helen Susan Kim reported her initial beneficial ownership in the company as of January 8, 2026. Most of the reported holdings are indirect interests in Series A and Series B Redeemable Convertible Preferred Stock held by Vida Ventures II, LLC and Vida Ventures II-A, LLC, where investment and voting decisions may be made through affiliated management entities and committees, and each participant only benefits to the extent of their pecuniary interest.
Each share of Series A and Series B preferred stock is convertible into common stock on a 3.8044-for-1 basis and is expected to convert automatically into common shares immediately before the closing of an initial public offering of Aktis Oncology common stock without additional payment. Kim also holds a stock option for 37,866 common shares at $18 per share, with 1/36 of the option vesting monthly starting January 8, 2026, subject to her continued service.